Adjuvant Docetaxel and Cyclophosphamide With or Without Epirubicin for Early Breast Cancer: Final Analysis of the Randomized DBCG 07-READ Trial First, patient-level correlation was confirmed using ...
Explore 2026 CLL frontline choices, from all-oral acalabrutinib–venetoclax to MRD-guided care, plus pipeline advances and ...
Combination of Osimertinib and Vascular Endothelial Growth Factor Receptor Inhibitors for EGFR-Mutated Non–Small Cell Lung Cancer: Old or New Regimen? In the article that accompanies this editorial, ...
Clinical Trials Arena on MSN
Lilly’s Jaypirca racks up fourth phase III CLL win
GlobalData predicts Lilly’s Jaypirca to generate $1.34bn in CLL sales alone in 2032.
Most patients initiated full-dose ibrutinib, while reduced starting doses clustered in older, more comorbid, poorer ECOG ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results